H. D. Jager

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

B. Heijmen, S. Aluwini, L. Incrocci, 2016, The Lancet. Oncology.

OC-0218 ACUTE TOXICITY OF THE RANDOMIZED PHASE III DUTCH HYPOFRACTIONATION TRIAL (HYPRO) FOR PROSTATE CANCER

W. Ghidey, M. Dirkx, S. Aluwini, 2012 .

OC-0052: Late toxicity in the randomized phase III Dutch Hypofractionation Trial for prostate cancer patients (HYPRO)

W. Ghidey, M. Dirkx, S. Aluwini, 2013 .